Logo for Kura Oncology Inc

Kura Oncology Investor Relations Material

Latest events

Logo for Kura Oncology Inc

Investor Update

Kura Oncology
Logo for Kura Oncology

Investor Update

30 Jan, 2024
Logo for Kura Oncology

Q3 2023

2 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.